Drug profile · INN
atazanavir sulfate
REYATAZ
atazanavir sulfate (REYATAZ) is a human immunodeficiency virus type 1 protease inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — atazanavir sulfate
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.89
Quick answer
atazanavir sulfate (REYATAZ) is a human immunodeficiency virus type 1 protease inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Human immunodeficiency virus type 1 protease inhibitor
Primary target: Human immunodeficiency virus type 1 protease
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is atazanavir sulfate?
atazanavir sulfate (REYATAZ) is a human immunodeficiency virus type 1 protease inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for atazanavir sulfate?
REYATAZ is a marketed brand name for atazanavir sulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of atazanavir sulfate?
atazanavir sulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.